


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

XUANZHU BIOPHARM INCLUDED AS A CONSTITUENT STOCK OF THE HANG SENG COMPOSITE INDEX

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, based on the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025 announced by Hang Seng Indexes Company Limited on 13 February 2026, the Group’s non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”, listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 15 October 2025, stock code: 2575), has been included as a constituent stock of the Hang Seng Composite Index. The adjustment will take effect on 9 March 2026.

As a comprehensive benchmark index for the Hong Kong stock market, the Hang Seng Composite Index fully covers listed companies listed on the Main Board of the Stock Exchange with a cumulative market capitalisation ranking among the top 95%. Following its inclusion as a constituent stock of the Hang Seng Composite Index, shares of Xuanzhu Biopharm are expected to meet the eligibility criteria for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, which serve as channels for securities trading and investment between capital market investors in Hong Kong and Mainland China.

The inclusion of Xuanzhu Biopharm in the Hang Seng Composite Index not only reflects investors' recognition of Xuanzhu Biopharm's value and growth potential, but also demonstrates the market's affirmation of the Group's innovative pharmaceutical business layout and development strategy, marking an important achievement of the Group's in-depth development and continuous breakthroughs in the innovative drug sector. The Group expects such inclusion to enhance the liquidity of Xuanzhu Biopharm's shares, expand its investor base and diversify its shareholder structure, thereby further elevating Xuanzhu Biopharm's reputation and investment value in the capital market, which is conducive to the long-term and stable development of Xuanzhu Biopharm, and will also bring positive impacts to the Group.

The Board would like to express its sincere gratitude to all shareholders, investors and partners for their long-term trust and support. Going forward, the Group will continue to adhere to the innovation-driven development philosophy, persistently focus on its two core segments of medical aesthetic and innovative pharmaceuticals, and deepen its global layout. Meanwhile, the Group will fully support the business development of Xuanzhu Biopharm, promote its continuous delivery of innovative achievements and enhancement of commercialisation capabilities, and work hand-in-hand with all shareholders, investors and partners to create greater value for shareholders.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights. The company has a first-class R&D team, all core personnel have years of experience in new drug research and development. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 22 February 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.